Scalper1 News
Baxter International (BAX) announced Thursday that it will split its biopharma and medical-products businesses into two separate companies by mid-2015. Baxter stock jumped 5% in heavy morning trading in the stock market today. The biopharma arm, which took in about $6 billion last year, is devoted mainly to hemophilia treatments and other blood-related products. The branch accounts for less than half of sales but a majority of profits. However, it Scalper1 News
Scalper1 News